{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:24:47Z","timestamp":1790101487724,"version":"4.0.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40291-025-00817-2","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:02:22Z","timestamp":1761883342000},"page":"75-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancing Medulloblastoma Treatment: Molecular Mechanisms, Drug Repurposing, and Precision Therapies"],"prefix":"10.1007","volume":"30","author":[{"given":"Mohammed A.","family":"Abdel-Rasol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-1417","authenticated-orcid":false,"given":"Wael M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","unstructured":"Alsaedi MA, Strathdee G. The role of DNA methylation in directing treatment in medulloblastoma. Epigenomics. 2025;1\u201312. https:\/\/doi.org\/10.1080\/17501911.2025.2554570.","DOI":"10.1080\/17501911.2025.2554570"},{"key":"817_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41571-021-00478-0","volume":"18","author":"P Sidaway","year":"2021","unstructured":"Sidaway P. Medulloblastoma: prognostic subtypes revealed. Nat Rev Clin Oncol. 2021;18:131\u20132.","journal-title":"Nat Rev Clin Oncol"},{"key":"817_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/cas.15691","volume":"114","author":"Y Funakoshi","year":"2023","unstructured":"Funakoshi Y, Sugihara Y, Uneda A, Nakashima T, Suzuki H. Recent advances in the molecular understanding of medulloblastoma. Cancer Sci. 2023;114:741\u20139.","journal-title":"Cancer Sci"},{"key":"817_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noae178","volume":"27","author":"EC Schwalbe","year":"2025","unstructured":"Schwalbe EC, Lindsey JC, Danilenko M, Hill RM, Crosier S, Ryan SL, et al. Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study. Neuro Oncol. 2025;27:222\u201336.","journal-title":"Neuro Oncol"},{"key":"817_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/cancers15041215","volume":"15","author":"C Kerstens","year":"2023","unstructured":"Kerstens C, Wildiers HP, Schroyen G, Almela M, Mark RE, Lambrecht M, et al. A systematic review on the potential acceleration of neurocognitive aging in older cancer survivors. Cancers. 2023;15:1215.","journal-title":"Cancers"},{"key":"817_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","volume":"20","author":"K Mitusova","year":"2022","unstructured":"Mitusova K, Peltek OO, Karpov TE, Muslimov AR, Zyuzin MV, Timin AS. Overcoming the blood\u2013brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnol. 2022;20:412.","journal-title":"J Nanobiotechnol"},{"key":"817_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/cancers17030439","volume":"17","author":"JS Rechberger","year":"2025","unstructured":"Rechberger JS, Toll SA, Biswas S, You HB, Chow WD, Kendall N, et al. Advances in the repurposing and blood\u2013brain barrier penetrance of drugs in pediatric brain tumors. Cancers. 2025;17:439.","journal-title":"Cancers"},{"key":"817_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2174\/1574892816666210208232251","volume":"16","author":"D Fong","year":"2021","unstructured":"Fong D, Christensen CT, Chan MM. Targeting cancer stem cells with repurposed drugs to improve current therapies. Recent Pat Anticancer Drug Discov. 2021;16:136\u201360.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"5","key":"817_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.21873\/anticanres.15703","volume":"42","author":"T Sursal","year":"2022","unstructured":"Sursal T, Ronecker JS, Dicpinigaitis AJ, Mohan AL, Tobias ME, Gandhi CD, et al. Molecular stratification of medulloblastoma: clinical outcomes and therapeutic interventions. Anticancer Res. 2022;42(5):2225\u201339.","journal-title":"Anticancer Res"},{"key":"817_CR10","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/cells11162523","volume":"11","author":"C Suchors","year":"2022","unstructured":"Suchors C, Kim J. Canonical hedgehog pathway and noncanonical GLI transcription factor activation in cancer. Cells. 2022;11:2523.","journal-title":"Cells"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3390\/cancers15092525","volume":"15","author":"N Stepien","year":"2023","unstructured":"Stepien N, Senfter D, Furtner J, Haberler C, Dorfer C, Czech T, et al. Proof-of-concept for liquid biopsy disease monitoring of MYC-amplified group 3 medulloblastoma by droplet digital PCR. Cancers. 2023;15:2525.","journal-title":"Cancers"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/noab178","volume":"24","author":"S Richardson","year":"2022","unstructured":"Richardson S, Hill RM, Kui C, Lindsey JC, Grabovksa Y, Keeling C, et al. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro Oncol. 2022;24:153\u201365.","journal-title":"Neuro Oncol"},{"key":"817_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/0113816128277350231219062154","volume":"30","author":"D Sokolov","year":"2024","unstructured":"Sokolov D, Sharda N, Banerjee A, Denisenko K, Basalious EB, Shukla H, et al. Differential signaling pathways in medulloblastoma: nano-biomedicine targeting non-coding epigenetics to improve current and future therapeutics. Curr Pharm Des. 2024;30:31\u201347.","journal-title":"Curr Pharm Des"},{"key":"817_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01761-7","volume":"16","author":"D Kumar","year":"2025","unstructured":"Kumar D, Kanchan R, Chaturvedi NK. Targeting protein synthesis pathways in MYC-amplified medulloblastoma. Discov Oncol. 2025;16:23.","journal-title":"Discov Oncol"},{"key":"817_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiaf092","volume":"117","author":"Y Sun","year":"2025","unstructured":"Sun Y, Xu Z, Wang Z, Zhang Y, Zhang P, Sheng L, et al. KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis. J Leukoc Biol. 2025;117:qiaf092.","journal-title":"J Leukoc Biol"},{"key":"817_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/10935266211036680","volume":"25","author":"N Kanit","year":"2022","unstructured":"Kanit N, Uysal Yoca O, Ince D, Olgun N, Ozer E. Gene-specific DNA methylation profiles in pediatric medulloblastomas. Pediatr Dev Pathol. 2022;25:82\u201390.","journal-title":"Pediatr Dev Pathol"},{"key":"817_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/cancers14010139","volume":"14","author":"MS Westphal","year":"2021","unstructured":"Westphal MS, Lee E, Schadt EE, Sholler GS, Zhu J. Identification of let-7 miRNA activity as a prognostic biomarker of SHH medulloblastoma. Cancers. 2021;14:139.","journal-title":"Cancers"},{"issue":"20","key":"817_CR18","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.3390\/cancers14205009","volume":"14","author":"NF van Bree","year":"2022","unstructured":"van Bree NF, Wilhelm M. The tumor microenvironment of medulloblastoma: an intricate multicellular network with therapeutic potential. Cancers. 2022;14(20):5009.","journal-title":"Cancers"},{"issue":"9","key":"817_CR19","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/neuonc\/noab031","volume":"23","author":"A Korshunov","year":"2021","unstructured":"Korshunov A, Okonechnikov K, Stichel D, Ryzhova M, Schrimpf D, Sahm F, et al. Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. Neuro Oncol. 2021;23(9):1576\u201385.","journal-title":"Neuro Oncol"},{"key":"817_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115697","volume":"215","author":"L Manfreda","year":"2023","unstructured":"Manfreda L, Rampazzo E, Persano L, Viola G, Bortolozzi R. Surviving the hunger games: metabolic reprogramming in medulloblastoma. Biochem Pharmacol. 2023;215:115697.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"817_CR21","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/febs.15817","volume":"289","author":"TE Werbowetski-Ogilvie","year":"2022","unstructured":"Werbowetski-Ogilvie TE. From sorting to sequencing in the molecular era: the evolution of the cancer stem cell model in medulloblastoma. FEBS J. 2022;289(7):1765\u201378.","journal-title":"FEBS J"},{"key":"817_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.744739","volume":"11","author":"JE Minturn","year":"2021","unstructured":"Minturn JE, Mochizuki AY, Partap S, Belasco JB, Lange BJ, Li Y, et al. A pilot study of low-dose craniospinal irradiation in patients with newly diagnosed average-risk medulloblastoma. Front Oncol. 2021;11:744739.","journal-title":"Front Oncol"},{"issue":"2","key":"817_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.33371\/ijoc.v19i2.1231","volume":"19","author":"CTU Banjarnahor","year":"2025","unstructured":"Banjarnahor CTU, Nainggolan A, Hariyanto AD. Craniospinal irradiation in adult medulloblastoma: a case report and analysis of treatment planning comparing volumetric modulated arc therapy and three-dimensional conformal radiotherapy. Indones J Cancer. 2025;19(2):305\u201310.","journal-title":"Indones J Cancer"},{"issue":"1","key":"817_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10238-025-01648-5","volume":"25","author":"Z Pan","year":"2025","unstructured":"Pan Z, Bao J, Wei S. Advancing medulloblastoma therapy: strategies and survival insights. Clin Exp Med. 2025;25(1):119.","journal-title":"Clin Exp Med"},{"issue":"1","key":"817_CR25","first-page":"84","volume":"1","author":"MV Dias","year":"2021","unstructured":"Dias MV, Isom B, Poole K, Triplett S, Sadanandan N. Evaluating the efficacy of targeted inhibitor therapeutics for Sonic Hedgehog medulloblastoma: significant milestones and current limitations. Georget Sci Res J. 2021;1(1):84\u201398.","journal-title":"Georget Sci Res J"},{"issue":"1","key":"817_CR26","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1038\/s41467-025-59612-6","volume":"16","author":"J Talbot","year":"2025","unstructured":"Talbot J, Fombonne J, Torrejon J, Babcock BR, McSwain LF, Rama N, et al. Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival. Nat Commun. 2025;16(1):5137.","journal-title":"Nat Commun"},{"issue":"6","key":"817_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","volume":"24","author":"JR Whitfield","year":"2025","unstructured":"Whitfield JR, Soucek L. MYC in cancer: from undruggable target to clinical trials. Nat Rev Drug Discov. 2025;24(6):445\u201357.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"817_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14740338.2024.2348566","volume":"24","author":"H Ding","year":"2025","unstructured":"Ding H, Xu W, Dai M, Li S, Xin W, Tong Y, et al. Hematological toxicity of cyclin-dependent kinase 4\/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study. Expert Opin Drug Saf. 2025;24(2):157\u201365.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"817_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41388-024-03232-9","volume":"44","author":"J Yu","year":"2025","unstructured":"Yu J, Han J, Yu M, Rui H, Sun A, Li H. EZH2 inhibition sensitizes MYC-high medulloblastoma cancers to PARP inhibition by regulating NUPR1-mediated DNA repair. Oncogene. 2025;44(6):391\u2013405.","journal-title":"Oncogene"},{"issue":"1","key":"817_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113696","volume":"431","author":"J Ling","year":"2023","unstructured":"Ling J, Tang Z, Yang W, Li Y, Dong X. Pygo2 activates BRPF1 via Pygo2\u2013H3K4me2\/3 interaction to maintain malignant progression in colon cancer. Exp Cell Res. 2023;431(1):113696.","journal-title":"Exp Cell Res"},{"issue":"7","key":"817_CR31","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.3390\/ijms24076733","volume":"24","author":"N Pe\u0107ina-\u0160laus","year":"2023","unstructured":"Pe\u0107ina-\u0160laus N, Ani\u010di\u0107 S, Bukovac A, Kafka A. Wnt signaling inhibitors and their promising role in tumor treatment. Int J Mol Sci. 2023;24(7):6733.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"817_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/14737140.2021.1932472","volume":"21","author":"MR Paul","year":"2021","unstructured":"Paul MR, Zage PE. Overview and recent advances in the targeting of medulloblastoma cancer stem cells. Expert Rev Anticancer Ther. 2021;21(9):957\u201374.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"817_CR33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41467-024-54858-y","volume":"16","author":"K Desai","year":"2025","unstructured":"Desai K, Wanggou S, Luis E, Whetstone H, Yu C, Vanner RJ, et al. Olig2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma. Nat Commun. 2025;16(1):1092.","journal-title":"Nat Commun"},{"key":"817_CR34","doi-asserted-by":"publisher","first-page":"1557313","DOI":"10.3389\/fonc.2025.1557313","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li S, Wang Y, Liu J, Liu Y, Gong X, et al. Tumor-associated macrophages correlate with better outcome in SHH medulloblastoma. Front Oncol. 2025;15:1557313.","journal-title":"Front Oncol"},{"key":"817_CR35","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu L, et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1563303.","journal-title":"Front Immunol"},{"issue":"5","key":"817_CR36","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-24-1465","volume":"15","author":"A Timpanaro","year":"2025","unstructured":"Timpanaro A, Song EZ, Amwas N, Chiu CH, Ronsley R, Taylor MR, et al. Evolving CAR T-cell therapy to overcome the barriers in treating pediatric central nervous system tumors. Cancer Discov. 2025;15(5):890\u2013902.","journal-title":"Cancer Discov"},{"issue":"14","key":"817_CR37","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.3390\/cancers13143524","volume":"13","author":"L Bitar","year":"2021","unstructured":"Bitar L, Schumann U, K\u00f6nig R, Zipp F, Schmidt MH. Targeting immune modulators in glioma while avoiding autoimmune conditions. Cancers. 2021;13(14):3524.","journal-title":"Cancers"},{"issue":"4","key":"817_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/antib12040074","volume":"12","author":"R Ramapriyan","year":"2023","unstructured":"Ramapriyan R, Sun J, Curry A, Richardson LG, Ramesh T, Gaffey MA, et al. The role of antibody-based therapies in neuro-oncology. Antibodies. 2023;12(4):74.","journal-title":"Antibodies"},{"issue":"6","key":"817_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063225","volume":"25","author":"C Belgiovine","year":"2024","unstructured":"Belgiovine C, Mebelli K, Raffaele A, De Cicco M, Rotella J, Pedrazzoli P, et al. Pediatric solid cancers: dissecting the tumor microenvironment to improve the results of clinical immunotherapy. Int J Mol Sci. 2024;25(6):3225.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"817_CR40","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/pharmaceutics16080986","volume":"16","author":"M Toropko","year":"2024","unstructured":"Toropko M, Chuvpilo S, Karabelsky A. Mirna-mediated mechanisms in the generation of effective and safe oncolytic viruses. Pharmaceutics. 2024;16(8):986.","journal-title":"Pharmaceutics"},{"issue":"6","key":"817_CR41","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12094-021-02762-y","volume":"24","author":"S Li","year":"2022","unstructured":"Li S, Poolen GC, van Vliet LC, Schipper JG, Broekhuizen R, Monnikhof M, et al. Pediatric medulloblastoma express immune checkpoint B7\u2013H3. Clin Transl Oncol. 2022;24(6):1204\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"817_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.31083\/j.fbl2704121","volume":"27","author":"V Golubovskaya","year":"2022","unstructured":"Golubovskaya V. CAR-T cells targeting immune checkpoint pathway players. Front Biosci (Landmark Ed). 2022;27(4):121.","journal-title":"Front Biosci (Landmark Ed)."},{"issue":"7","key":"817_CR43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/pathogens14070629","volume":"14","author":"H Preston","year":"2025","unstructured":"Preston H, Casey R, Ferris E, et al. Human cytomegalovirus immune evasion of natural killer cells: a virus for all seasons? Pathogens. 2025;14(7):629. https:\/\/doi.org\/10.3390\/pathogens14070629.","journal-title":"Pathogens"},{"issue":"6","key":"817_CR44","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/pharmaceutics17060706","volume":"17","author":"L Ding","year":"2025","unstructured":"Ding L, Kshirsagar P, Agrawal P, Murry DJ. Crossing the blood\u2013brain barrier: innovations in receptor- and transporter-mediated transcytosis strategies. Pharmaceutics. 2025;17(6):706.","journal-title":"Pharmaceutics"},{"issue":"12","key":"817_CR45","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/pharmaceutics16121611","volume":"16","author":"Y Jiao","year":"2024","unstructured":"Jiao Y, Yang L, Wang R, Song G, Fu J, Wang J, et al. Drug delivery across the blood\u2013brain barrier: a new strategy for the treatment of neurological diseases. Pharmaceutics. 2024;16(12):1611.","journal-title":"Pharmaceutics"},{"key":"817_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.dscb.2024.100151","author":"DM Modi","year":"2024","unstructured":"Modi DM, Modi AD. Nanogel-mediated therapeutic delivery across blood\u2013cerebrospinal fluid and blood\u2013spinal cord barriers. Brain Disorders. 2024. https:\/\/doi.org\/10.1016\/j.dscb.2024.100151.","journal-title":"Brain Disorders"},{"issue":"10","key":"817_CR47","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.7150\/thno.69682","volume":"12","author":"DH Upton","year":"2022","unstructured":"Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood\u2013brain barrier for brain cancer therapy. Theranostics. 2022;12(10):4734.","journal-title":"Theranostics."},{"issue":"2","key":"817_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ibra.12198","volume":"11","author":"S Tarantino","year":"2025","unstructured":"Tarantino S, Bianco A, De Matteis V, Scarpa E, Rinaldi R. Nanotechnology in brain cancer treatment: the role of gold nanoparticles as therapeutic enhancers. ibrain. 2025;11(2):119\u201345.","journal-title":"ibrain"},{"issue":"2","key":"817_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/pharmaceutics15020505","volume":"15","author":"L Abballe","year":"2023","unstructured":"Abballe L, Spinello Z, Antonacci C, Coppola L, Miele E, Catanzaro G, et al. Nanoparticles for drug and gene delivery in pediatric brain tumors\u2019 cancer stem cells: current knowledge and future perspectives. Pharmaceutics. 2023;15(2):505.","journal-title":"Pharmaceutics"},{"issue":"5","key":"817_CR50","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.3390\/curroncol30050379","volume":"30","author":"B Yao","year":"2023","unstructured":"Yao B, Delaidelli A, Vogel H, Sorensen PH. Pediatric brain tumours: lessons from the immune microenvironment. Curr Oncol. 2023;30(5):5024\u201346.","journal-title":"Curr Oncol"},{"issue":"11","key":"817_CR51","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","volume":"39","author":"AP Liu","year":"2021","unstructured":"Liu AP, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021;39(11):1519\u201330.","journal-title":"Cancer Cell"},{"issue":"1","key":"817_CR52","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1038\/s41598-021-85178-6","volume":"11","author":"Y Sun","year":"2021","unstructured":"Sun Y, Li M, Ren S, Liu Y, Zhang J, Li S, et al. Exploring genetic alterations in circulating tumor DNA from cerebrospinal fluid of pediatric medulloblastoma. Sci Rep. 2021;11(1):5638.","journal-title":"Sci Rep"},{"issue":"2","key":"817_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13577-025-01181-3","volume":"38","author":"JO de Santis","year":"2025","unstructured":"de Santis JO, de Sousa GR, Queiroz RGDP, C\u00e2ndido MF, Almeida F, de Rezende CP, et al. Immunomodulatory role of exosome-derived content in pediatric medulloblastoma: a molecular subgroup perspective. Hum Cell. 2025;38(2):55.","journal-title":"Hum Cell"},{"issue":"10","key":"817_CR54","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/0008-5472.CAN-21-0871","volume":"82","author":"N Gabriel","year":"2022","unstructured":"Gabriel N, Balaji K, Jayachandran K, Inkman M, Zhang J, Dahiya S, et al. Loss of H3K27 trimethylation promotes radiotherapy resistance in medulloblastoma and induces an actionable vulnerability to BET inhibition. Cancer Res. 2022;82(10):2019\u201330.","journal-title":"Cancer Res"},{"issue":"7","key":"817_CR55","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ccell.2024.06.002","volume":"42","author":"YRJ Wang","year":"2024","unstructured":"Wang YRJ, Wang P, Yan Z, Zhou Q, Gunturkun F, Li P, et al. Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures. Cancer Cell. 2024;42(7):1239\u201357.","journal-title":"Cancer Cell"},{"issue":"5","key":"817_CR56","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1177\/02841851221143496","volume":"64","author":"M Karabacak","year":"2023","unstructured":"Karabacak M, Ozkara BB, Ozturk A, Kaya B, Cirak Z, Orak E, et al. Radiomics-based machine learning models for prediction of medulloblastoma subgroups: a systematic review and meta-analysis of the diagnostic test performance. Acta Radiol. 2023;64(5):1994\u20132003.","journal-title":"Acta Radiol"},{"issue":"1","key":"817_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-023-04526-w","volume":"166","author":"S Zeuner","year":"2024","unstructured":"Zeuner S, Vollmer J, Sigaud R, Oppermann S, Peterziel H, ElHarouni D, et al. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells. J Neurooncol. 2024;166(1):99\u2013112.","journal-title":"J Neurooncol"},{"issue":"3","key":"817_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12981","volume":"50","author":"MP Jensen","year":"2024","unstructured":"Jensen MP, Qiang Z, Khan DZ, Stoyanov D, Baldeweg SE, Jaunmuktane Z, et al. Artificial intelligence in histopathological image analysis of central nervous system tumours: a systematic review. Neuropathol Appl Neurobiol. 2024;50(3):e12981.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"817_CR59","doi-asserted-by":"publisher","first-page":"1233657","DOI":"10.3389\/fgene.2023.1233657","volume":"14","author":"E Sharif Rahmani","year":"2023","unstructured":"Sharif Rahmani E, Lawarde A, Lingasamy P, Moreno SV, Salumets A, Modhukur V. Mbmethpred: a computational framework for the accurate classification of childhood medulloblastoma subgroups using data integration and AI-based approaches. Front Genet. 2023;14:1233657.","journal-title":"Front Genet"},{"issue":"1","key":"817_CR60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40478-024-01831-x","volume":"12","author":"F Tsiami","year":"2024","unstructured":"Tsiami F, Lago C, Pozza N, Piccioni F, Zhao X, L\u00fclsberg F, et al. Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma. Acta Neuropathol Commun. 2024;12(1):125.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"817_CR61","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2478\/aoas-2024-0078","volume":"25","author":"D Maj","year":"2025","unstructured":"Maj D, G\u00f3rka K. Applications of CRISPR\/Cas9 technology in mice and livestock genome editing: current research. Ann Anim Sci. 2025;25(2):467\u201381.","journal-title":"Ann Anim Sci"},{"issue":"1","key":"817_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/biom13010061","volume":"13","author":"Z Ga\u00e1l","year":"2022","unstructured":"Ga\u00e1l Z. Targeted epigenetic interventions in cancer with an emphasis on pediatric malignancies. Biomolecules. 2022;13(1):61.","journal-title":"Biomolecules"},{"issue":"12","key":"817_CR63","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202318199","volume":"15","author":"C Lago","year":"2023","unstructured":"Lago C, Federico A, Leva G, Mack NL, Schwalm B, Ballabio C, et al. Patient-and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments. EMBO Mol Med. 2023;15(12):e18199.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"817_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-024-02283-x","volume":"11","author":"SV Kapplingattu","year":"2025","unstructured":"Kapplingattu SV, Bhattacharya S, Adlakha YK. Mirnas as major players in brain health and disease: current knowledge and future perspectives. Cell Death Discov. 2025;11(1):7.","journal-title":"Cell Death Discov"},{"issue":"7","key":"817_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70406","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Li J, Du F, Deng H. Cancer stem cells: bridging microenvironmental interactions and clinical therapy. Clin Transl Med. 2025;15(7):e70406.","journal-title":"Clin Transl Med"},{"key":"817_CR66","doi-asserted-by":"publisher","first-page":"1485886","DOI":"10.3389\/fonc.2025.1485886","volume":"15","author":"H Ogawa","year":"2025","unstructured":"Ogawa H, Yoshida K, Hasegawa S, Wada H, Yasui M, Tahara H. Significance of mouse xenograft tumor model using patient-derived cancer organoids for clinical drug development. Front Oncol. 2025;15:1485886.","journal-title":"Front Oncol"},{"issue":"1","key":"817_CR67","doi-asserted-by":"publisher","first-page":"vdae218","DOI":"10.1093\/noajnl\/vdae218","volume":"7","author":"MJ van Essen","year":"2025","unstructured":"van Essen MJ, Nicheperovich A, Schuster-B\u00f6ckler B, Becker EB, Jacob J. Sonic hedgehog medulloblastoma cells in co-culture with cerebellar organoids converge towards in vivo malignant cell states. Neuro-Oncol Adv. 2025;7(1):vdae218.","journal-title":"Neuro-Oncol Adv."},{"key":"817_CR68","doi-asserted-by":"publisher","unstructured":"Li Y, Lim C, Dismuke T, Malawsky DS, Oasa S, Bruce ZC, et al. Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179. Nat Commun [Internet]. 2025;16(1):1091. https:\/\/doi.org\/10.1038\/s41467-024-54861-3.","DOI":"10.1038\/s41467-024-54861-3"},{"issue":"1","key":"817_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00381-025-06810-8","volume":"41","author":"VG Collins","year":"2025","unstructured":"Collins VG, Kanodia C, Yahya QB, Liistro M, Kaliaperumal C. 5-aminolevulinic acid (5-ALA) in paediatric brain tumour surgery: a systematic review and exploration of fluorophore alternatives. Childs Nerv Syst. 2025;41(1):1\u201312.","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"817_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/cnx2.70003","volume":"1","author":"H Chen","year":"2025","unstructured":"Chen H, Zhang G, Qian Y, Peng Y, Li X, Wang J, et al. Advancements in the application of the intersection of medicine and engineering in cancer research. Cancer Nexus. 2025;1(1):e70003.","journal-title":"Cancer Nexus"},{"issue":"13","key":"817_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132221","volume":"17","author":"SM Faisal","year":"2025","unstructured":"Faisal SM, Yadav M, Gibson GR, Klinestiver AT, Sorenson RM, Cantor E, et al. Current landscape of preclinical models for pediatric gliomas: clinical implications and future directions. Cancers (Basel). 2025;17(13):2221.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"817_CR72","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1158\/1078-0432.CCR-24-2754","volume":"31","author":"AL Green","year":"2025","unstructured":"Green AL, Minard CG, Liu X, Safgren SL, Pinkney K, Harris L, et al. Phase I trial of selinexor in pediatric recurrent\/refractory solid and CNS tumors (ADVL1414): a Children\u2019s Oncology Group Phase I Consortium trial. Clin Cancer Res. 2025;31(9):1587\u201395.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"817_CR73","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ame2.12399","volume":"8","author":"J Gao","year":"2025","unstructured":"Gao J, Zhao Y, Wang Z, Liu F, Chen X, Mo J, et al. Single-cell transcriptomic sequencing identifies subcutaneous patient-derived xenograft recapitulated medulloblastoma. Anim Model Exp Med. 2025;8(3):458\u201372.","journal-title":"Anim Model Exp Med"},{"issue":"1","key":"817_CR74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41746-024-01402-3","volume":"8","author":"M De Domenico","year":"2025","unstructured":"De Domenico M, Allegri L, Caldarelli G, d\u2019Andrea V, Di Camillo B, Rocha LM, et al. Challenges and opportunities for digital twins in precision medicine from a complex systems perspective. NPJ Digit Med. 2025;8(1):37.","journal-title":"NPJ Digit Med"},{"issue":"2","key":"817_CR75","volume":"14","author":"SB Nadin","year":"2025","unstructured":"Nadin SB, Cuello-Carri\u00f3n FD, Cayado-Guti\u00e9rrez N, Fanelli MA. Overview of Wnt\/\u03b2-catenin pathway and DNA damage\/repair in cancer. Biology (Basel). 2025;14(2):185.","journal-title":"Biology (Basel)"},{"issue":"9","key":"817_CR76","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/biom11091275","volume":"11","author":"R Kumavath","year":"2021","unstructured":"Kumavath R, Paul S, Pavithran H, Paul MK, Ghosh P, Barh D, et al. Emergence of cardiac glycosides as potential drugs: current and future scope for cancer therapeutics. Biomolecules. 2021;11(9):1275.","journal-title":"Biomolecules"},{"key":"817_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113616","volume":"154","author":"CL Li","year":"2022","unstructured":"Li CL, Fang ZX, Wu Z, Hou YY, Wu HT, Liu J. Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy. Biomed Pharmacother. 2022;154:113616.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"817_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10238-025-01631-0","volume":"25","author":"MS Anwer","year":"2025","unstructured":"Anwer MS, Abdel-Rasol MA, El-Sayed WM. Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations. Clin Exp Med. 2025;25(1):117.","journal-title":"Clin Exp Med"},{"key":"817_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.911876","volume":"12","author":"W Huang","year":"2022","unstructured":"Huang W, Hao Z, Mao F, Guo D. Small molecule inhibitors in adult high-grade glioma: from the past to the future. Front Oncol. 2022;12:911876.","journal-title":"Front Oncol"},{"key":"817_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111846","volume":"131","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang Z, Li S, Ma J, Dai X, Lu J. Deciphering JAK\/STAT signaling pathway: a multifaceted approach to tumorigenesis, progression and therapeutic interventions. Int Immunopharmacol. 2024;131:111846.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"817_CR81","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41467-023-36847-9","volume":"14","author":"OJ Mainwaring","year":"2023","unstructured":"Mainwaring OJ, Weishaupt H, Zhao M, Ros\u00e9n G, Borgenvik A, Breinschmid L, et al. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nat Commun. 2023;14(1):1221.","journal-title":"Nat Commun"},{"key":"817_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957373","volume":"12","author":"A Roy","year":"2022","unstructured":"Roy A, Bera S, Saso L, Dwarakanath BS. Role of autophagy in tumor response to radiation: implications for improving radiotherapy. Front Oncol. 2022;12:957373.","journal-title":"Front Oncol"},{"issue":"13","key":"817_CR83","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400725RR","volume":"38","author":"S Cavalu","year":"2024","unstructured":"Cavalu S, Saber S, Amer AE, Hamad RS, Abdel-Reheim MA, Elmorsy EA, et al. The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: extending beyond cardiovascular disorders. FASEB J. 2024;38(13):e23813.","journal-title":"FASEB J"},{"issue":"10","key":"817_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13101201","volume":"13","author":"F Jamali","year":"2024","unstructured":"Jamali F, Lan K, Daniel P, Petrecca K, Sabri S, Abdulkarim B. Synergistic dual targeting of thioredoxin and glutathione systems irrespective of p53 in glioblastoma stem cells. Antioxidants. 2024;13(10):1201.","journal-title":"Antioxidants"},{"issue":"9","key":"817_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091752","volume":"16","author":"KO Holmberg","year":"2024","unstructured":"Holmberg KO, Borgenvik A, Zhao M, Giraud G, Swartling FJ. Drivers underlying metastasis and relapse in medulloblastoma and targeting strategies. Cancers (Basel). 2024;16(9):1752.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"817_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121601","volume":"17","author":"CT Roberts","year":"2024","unstructured":"Roberts CT, Raabe N, Wiegand L, Kadar Shahib A, Rastegar M. Diverse applications of the anti-diabetic drug metformin in treating human disease. Pharmaceuticals (Basel). 2024;17(12):1601.","journal-title":"Pharmaceuticals (Basel)"},{"key":"817_CR87","doi-asserted-by":"crossref","unstructured":"Majchrzak-Celi\u0144ska A, Warych A, Szoszkiewicz M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes. 2021;12(2):208.","DOI":"10.3390\/genes12020208"},{"issue":"8","key":"817_CR88","doi-asserted-by":"publisher","first-page":"2401860","DOI":"10.1002\/smtd.202401860","volume":"9","author":"Z Luo","year":"2025","unstructured":"Luo Z, Chen CY, Li S. Improving tumor targeting and penetration for nanoparticle-mediated cancer therapy. Small Methods. 2025;9(8):2401860.","journal-title":"Small Methods"},{"key":"817_CR89","doi-asserted-by":"publisher","first-page":"1554311","DOI":"10.3389\/fimmu.2025.1554311","volume":"16","author":"W Zhang","year":"2025","unstructured":"Zhang W, Xu Y, Fang Y, Li M, Li D, Guo H, et al. Ubiquitination in lipid metabolism reprogramming: implications for pediatric solid tumors. Front Immunol. 2025;16:1554311.","journal-title":"Front Immunol"},{"issue":"1","key":"817_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010251","volume":"26","author":"AL Nguyen","year":"2024","unstructured":"Nguyen AL, Facey CO, Boman BM. The significance of aldehyde dehydrogenase 1 in cancers. Int J Mol Sci. 2024;26(1):251.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"817_CR91","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MS9.0000000000002760","volume":"87","author":"M Shayestehfar","year":"2025","unstructured":"Shayestehfar M, Taherkhani T, Jahandideh P, Hamidieh AA, Faramarzpour M, Memari A. Brain tumors and induced pluripotent stem cell technology: a systematic review of the literature. Ann Med Surg. 2025;87(1):250\u201364.","journal-title":"Ann Med Surg"},{"issue":"2","key":"817_CR92","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050323","volume":"17","author":"MJ van Essen","year":"2024","unstructured":"van Essen MJ, Apsley EJ, Riepsaame J, Xu R, Northcott PA, Cowley SA, et al. PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis. Dis Model Mech. 2024;17(2):dmm050323.","journal-title":"Dis Model Mech"},{"key":"817_CR93","doi-asserted-by":"publisher","first-page":"1602930","DOI":"10.3389\/fimmu.2025.1602930","volume":"16","author":"A Poggi","year":"2025","unstructured":"Poggi A, Reggiani F, Azevedo H, Raffaghello L, Pereira RC. Medulloblastoma: biology and immunotherapy. Front Immunol. 2025;16:1602930.","journal-title":"Front Immunol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00817-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:02:58Z","timestamp":1769500978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00817-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00817-2","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohammed A. Abdel-Rasol and Wael M. El-Sayed have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and design of the study: MAA, WME. Supervision: WME. Writing original draft: MAA. Review and editing: WME. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}